Welgene Biotech Co.,Ltd. (TPEX:6661)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Biotechnology Testing Department	306.99M	243.40M	213.64M	242.01M	228.89M
Biotechnology Testing Department Growth	26.13%	13.93%	-11.73%	5.73%	-26.46%
Instrument Sales Department	68.95M	79.15M	66.91M	79.89M	83.76M
Instrument Sales Department Growth	-12.89%	18.29%	-16.24%	-4.63%	-3.56%
Total	375.94M	322.55M	280.55M	321.90M	312.65M
Total Growth	16.55%	14.97%	-12.85%	2.96%	-21.46%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Taiwan	375.94M	322.55M	280.55M	321.90M	312.65M
Taiwan Growth	16.55%	14.97%	-12.85%	2.96%	-21.46%
Total	375.94M	322.55M	280.55M	321.90M	312.65M
Total Growth	16.55%	14.97%	-12.85%	2.96%	-21.46%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 22, 2026

Data Sources Report a data error